relationships relevant to the contents of this paper to disclose. trials. In aggregate, these landmark studies provide a strong evidence basis for the efficacy and safety of digoxin therapy. In patients with HF with reduced EF, digoxin augments cardiac output (CO) and reduces pulmonary capillary wedge pressure without inducing potentially hazardous increases in heart rate or decreases in blood pressure (10, 11) . In addition, digoxin therapy improves signs and symptoms of HF and functional status (7, 8) . Similarly, digoxin reduced the incidence of all-cause, cardiovascular-related, and HF-specific hospitalizations in the DIG trial, which enrolled 6,800 stable ambulatory HF patients with an EF <45% (9). Interestingly, in the DIG ancillary trial, which enrolled 988 outpatients with HF with an EF >45%, digoxin use was associated with a trend towards a reduction in hospitalizations for worsening HF, which approached, but did not reach, the threshold for significance, perhaps in part due to the smaller sample size and reduced statistical power (12) . Although digoxin is known to have a narrow therapeutic window, the absolute incidence of digoxin toxicity is low, both in the controlled setting of a clinical trial (9) and in the context of everyday practice (13, 14) . For example, in the DIG trial, the incidence of hospitalization for suspected digoxin toxicity was 2-fold higher in digoxin-treated patients, yet the rate was low overall (i.e., 2.0% vs. 0.9%) (9).
Although no overall survival benefit was observed in the DIG trial, the effect of digoxin on the mode of death is intriguing. In essence, a bidirectional effect was observed: a decrease in mortality due to progressive pump failure that was offset by an increase in death due to other cardiovascular causes (9) .
However, secondary analyses of the DIG database have raised the hypothesis that digoxin may improve survival in pre-specified high-risk subgroups including patients with New York Heart Association functional class III or IV symptoms, an EF <25%, and/or a cardiothoracic ratio >55% (15). Similarly, although there were initially concerns on the basis of retrospective analyses of the DIG trial that digoxin might increase mortality in subsets of patients at risk
for digoxin toxicity such as women, the elderly, and patients with renal insufficiency, any potential detrimental effects on mortality are no longer significant after adjusting for serum digoxin concentration (SDC) (16) (17) (18) . In fact, a comprehensive post hoc analysis including all patients enrolled in the DIG main and ancillary trials found that digoxin use among patients with a SDC <1 ng/ml was associated with a robust survival benefit that was consistent across age, sex, EF, and comorbid disease states (16) .
As a result, the guidelines have been revised since the completion of the DIG trial and currently recommend a lower therapeutic SDC for HF (i.e., <1.0 ng/ml) (3).
More recently, the peer-reviewed published reports and the popular press have highlighted a number of studies showing potential harm with digoxin therapy in both HF and atrial fibrillation.
Notably, 2 independent research teams using differ- In conclusion, there have been no major advances in the pharmacological management of patients 
